期刊文献+

HPLC法测定盐酸奈必洛尔片中主药的含量 被引量:1

Content Determination of Main Component in Nebivolol Hydrochloride Tablets by HPLC
原文传递
导出
摘要 目的:建立以高效液相色谱法测定盐酸奈必洛尔片中主药含量的方法。方法:色谱柱为XTerra RP18,流动相为甲醇-0.03mo·lL-1磷酸二氢钾(0.68∶0.32),流速为1.0mL·min-1,检测波长为280nm,柱温为30℃。结果:盐酸奈必洛尔检测浓度线性范围为15.24~55.88μg·mL-1(r=0.9999,n=5);平均回收率为100.3%,RSD=0.74%(n=6)。结论:本方法简便、灵敏、准确,可用于盐酸奈必洛尔片中主药的含量测定。 OBJECTIVE:To establish an HPLC method for determination the content of main component in nebivolol hydrochloride tablets. METHODS:The XTerra RP18 column was used, the mobile phase consisted of methanol-0.03 mol·L-1 KH2PO4 solution(0.68 ∶ 0.32) at a flow rate of 1.0 mL·min-1,the detection wavelength was 280 nm, and the column temperature was 30 ℃. RESULTS:The linear range of nebivolol hydrochloride was 15.24~55.88 ?g·mL-1(r=0.999 9,n=5). The average recovery rate was 100.3% and RSD was 0.74% (n=6).CONCLUSION:The method is simple, sensitive, accurate and can be used for the determination of nebivolol hydrochloride tablets.
出处 《中国药房》 CAS CSCD 北大核心 2010年第33期3152-3153,共2页 China Pharmacy
关键词 盐酸奈必洛尔片 高效液相色谱法 含量测定 Nebivolol hydrochloride tablets HPLC Content determination
  • 相关文献

参考文献4

二级参考文献32

  • 1刘相星.新型β-阻滞剂奈必洛尔的临床降压效果(多中心研究结果)[J].心血管病学进展,2001,22(3):192-192.
  • 2王琼花.奈必洛尔首次在德国上市[J].World Pharm Newslett,1997,(8):23-23.
  • 3许英.奈必洛尔在英国上市[J].World Pharm Newslett,2000,(2):23-23.
  • 4Bridtow MR. What type of beta-blocker should be used to treat chronic heart failure[J]. Circulation ,2000,102(5) :484 - 486.
  • 5Kim MH,Devlin WH, Das SK, et al.Effects of beta-adrenergic blocking therapy on left ventricular diastolic relaxation properties in patients with dilated cardiomyopathy[ J ]. Circulation, 1999,100(7) : 729 - 735.
  • 6Metra M, Giubbini R, Nodari S, a d .Differential effects of betablockers in patients with heart failure: A prospective,randomized,double-blind comparison of the long-term effects of metoprolol versus carcvedilol[J].Circulation,2000,102(5):546-551
  • 7McNeely W,Goakl. Nebivolol in the management of essential hypertension[J]. Drugs, 1999,57(4) : 633 - 651.
  • 8Martijn AW,Pieteer A, Bas CAM, et al.Nebivolol:a Third-generation β-blocker that augments vascular nitric oxide release endothelial β2-Adrenergic receptor-mediated nitric oxide production[J]. Circulation, 2000,102 : 677 - 684.
  • 9De Cree J, Van Rooy P, Geukens H, et al. The antihypetensive and cardiac hemodynamic effects of nebivolol[ J ].Angiology,1992,43 (5) : 369 - 377.
  • 10Laeourciere Y, Poirier L, Lefebvre J. Comparative assessment of antihypertensive efficacy of DL-nebivolol and D-nebivolol in patients with confirmed mild to moderate hypertension[J] .J Cardiovasc Pharmacol, 1995,25(4) :619 - 624.

共引文献19

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部